InsiderTrades

Form 4 for AMGN Amgen

Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-05 · accession 0001127602-23-015044 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2023-05-09 2023-05-05 AMGN Gordon Murdo EVP, Gbl Commercial Ops F - Tax $231.89 -623 53.9K -1% -$144.5K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-05-05 F D 623 $231.89 53,866 D — — (F1) These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 on 5/2/2025 and 5/2/2026, and 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.